NIDA-CPU-0003

Division
DTMC
HEAL Study
No
Investigator(s)
Louis Cantilena, Jr., M.D, Ph.D.
Title
Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681
Short Description
This is a human laboratory clinical pharmacology study to assess potential interactions between intravenous (i.v.) cocaine and RPR 102681 administered in 3 escalating doses.
Release Date
May 23, 2017
Description

The primary objective of this study is to determine if there are significant interactions between RPR 102681 treatment concurrent with i.v. cocaine infusions of 0 and 40 mg by measuring adverse events and cardiovascular responses [heart rate (HR), blood pressure (BP), and electrocardiogram (ECG)].

Keywords
cocaine
interaction
phase 1b
rpr102681
stimulant
Assessments
Addiction Research Center Inventory
Beck Depression Inventory
Blood Cocaine Level
Blood Study Agent Level
Brief Psychiatric Rating Scale
Brief Substance Craving Scale
Brief Symptom Inventory
ECG Monitoring
Profile of Mood States
Visual Analog Scales
Vital Signs Monitoring
Accessibility Notice

Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.

Study Data
CPU-0003 Data
Study Links
ClinicalTrials.gov Link
CPU-0003 in NIH clinical trials registry
Study Documents
Protocol
CPU0003-Protocol.pdf
Dictionary
CPU0003-Dictionary.xlsx
Case Report Form(s)
CPU0003-CRF.pdf
Deidentification Notes
CPU0003-DeidentificationNotes.pdf
Nulled Values
CPU0003-NulledValues.csv
All Documents
CPU0003-AllDocuments.zip